The American Society of Hematology Honors Benjamin L. Ebert, MD, PhD, with the 2017 William Dameshek Prize
Published on: August 24, 2017
(WASHINGTON, August 24, 2017) – The American Society of
Hematology (ASH) will present the 2017 William Dameshek Prize to Benjamin L.
Ebert, MD, PhD, of Harvard Medical School, Brigham and Women’s Hospital, and
Dana-Farber Cancer Institute for his seminal discoveries in multiple areas of non-malignant
and malignant hematology.
The William Dameshek Prize is awarded to an early- or
mid-career hematologist who has made a recent outstanding contribution to the
field of hematology. This prize is named after the late William Dameshek, MD, a
past president of ASH and the original editor of Blood. ASH
President Kenneth C. Anderson, MD, a former recipient of this award, will
present this award to Dr. Ebert on Tuesday, December 12, during the 59th ASH Annual Meeting and
Exposition in Atlanta.
Dr. Ebert is a Professor of Medicine at Harvard Medical
School. He serves as Leader of the Leukemia Program for the
Dana-Farber/Harvard Cancer Center, an Institute Member at the Broad Institute,
and an Associate Physician at Brigham and Women’s Hospital. He has recently
been appointed Chair of Medical Oncology at Dana-Farber Cancer Institute.
Dr. Ebert is notable for his leadership in describing the
genomic landscape of adult myelodysplastic syndromes (MDS), including
identifying critical new roles for ribosomal dysfunction. Specifically, he
identified RPS14 as a key gene for deletion
5q MDS. His laboratory discovered
the molecular basis of lenalidomide activity in MDS as well as multiple
myeloma. Recent studies have
characterized clonal hematopoiesis and its contribution to both hematologic
malignancies and cardiovascular disease. Along with human genetic studies, Dr.
Ebert’s lab has made significant contributions to understanding the biological
basis of transformation of hematopoietic cells by somatic mutations. His work has demonstrated creativity, innovative
methodology, and direct human relevance.
Before beginning his medical career, Dr. Ebert was a Rhodes
Scholar, during which time he studied oxygen-regulated expression of the
erythropoietin gene at Oxford with Peter Ratcliffe. He received his MD from
Harvard Medical School in 1999, completed his internship and residency at Massachusetts
General Hospital in 2001, and went on to complete his clinical fellowship in hematology
and oncology at Dana-Farber Cancer Institute. Dr. Ebert completed his
postdoctoral research fellowship with Todd Golub at the Broad Institute of
Massachusetts Institute of Technology and Harvard University in 2007.
Dr. Ebert is an active member of ASH. He is currently
co-chair of the ASH Task Force on Precision Medicine, and has served as
Scientific Program Co-Chair for the 2014 ASH Annual Meeting and chair of the
ASH Committee on Myeloid Biology in 2012. He is currently President of the American
Society of Clinical Investigation and a member of the Association of American
Physicians. He has served on editorial boards, including Blood. In
addition to the William Dameshek Prize, his awards include the Harvard Medical
School Young Mentor Award, the Harvard-MIT Health Sciences and Technology
Program Thomas A. McMahon Mentoring Award, and the International Society for
Experimental Hematopoiesis Till and McCullough Award.
Society is honored to recognize Dr. Ebert as one of the leading young
investigators in hematology,” said
ASH President Kenneth C. Anderson, MD, of the Lebow Institute for Myeloma
Therapeutics and Jerome Lipper Myeloma Center at Dana-Farber Cancer Institute
in Boston. “Dr. Ebert is a rising star who has used innovative scientific approaches to transform our
basic understanding of hematopoiesis, which have already translated to novel
treatment paradigms in myelodysplasia and bone marrow failure disorders, and
will impact a much broader range of diseases in the future.”
The American Society of Hematology (www.hematology.org) is the world’s
largest professional society of hematologists dedicated to furthering the
understanding, diagnosis, treatment, and prevention of disorders affecting the
blood. For more than 50 years, the Society has led the development of
hematology as a discipline by promoting research, patient care, education,
training, and advocacy in hematology. ASH publishes Blood (www.bloodjournal.org),
the most cited peer-reviewed publication in the field, which is available
weekly in print and online. In 2016, ASH launched Blood Advances (www.bloodadvances.org), an
online, peer-reviewed open-access journal.
back to top
American Society of Hematology